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Acute pyelonephritis, frequently caused by Escherichia coli, is
a substantial health problem. Plasminogen activator inhibitor
type-1 (PAI-1) not only inhibits plasminogen activation but is
also involved in cell migration. To determine if it has a role in
host defense, we induced pyelonephritis in PAI-1 gene
knockout and wild-type mice by intravesical inoculation with
uropathogenic E. coli 1677. Bacterial growth was determined
on blood agar plates in portions of the kidneys homogenized
in sterile saline. Kidney levels of PAI-1 were increased in
infected compared to control mice, suggesting a
physiological role for PAI-1 during pyelonephritis. The
knockout mice had significantly more bacterial outgrowth in
kidney homogenates compared to the wild-type mice.
Strikingly, higher colony-forming units were accompanied by
increased levels of the cytokines TNF-a, IL-1b, and IL-6 in the
kidneys of knockout mice, but levels of the chemokines KC
and MIP-2 were not different. Remarkably, plasma levels of
KC were higher, but renal neutrophil influx was significantly
lower, in the knockout than in the wild-type mice. Our study
shows that PAI-1 is critically involved in host defense against
E. coli-induced acute pyelonephritis, in part, by modulating
neutrophil influx.
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Urinary tract infections (UTI) belong to the most frequently
occurring bacterial infections, affecting approximately 50%
of women at one point in their lifetime.1 In up to 95% of
cases, uropathogenic Escherichia coli is identified as the
causative organism.2 Although UTI usually display an
uncomplicated course, the upper urinary tract may become
involved by ascending infection, giving rise to the clinical
syndrome of acute pyelonephritis. When left untreated,
pyelonephritis may lead to renal fibrosis and subsequent end-
stage renal failure.3
Adhesion of uropathogenic E. coli to the urothelium will
trigger activation of several host defense mechanisms. After
inoculation with uropathogenic E. coli, bladder and tubular
epithelial cells have been shown to produce proinflammatory
cytokines and chemokines, among which interleukin-1b (IL-
1b), interleukin-6 (IL-6), and interleukin-8 (IL-8).4–6 Next,
the urothelium is invaded by neutrophils that phagocytose
and subsequently kill E. coli organisms.7
The plasminogen activator inhibitor type-1 (PAI-1)
belongs to the superfamily of serine protease inhibitors
(serpins) and is the principal physiological inhibitor of
tissue-type plasminogen activator and urokinase type plas-
minogen activator, thereby controlling plasmin generation
and regulating fibrinolysis.8 Besides its role as a regulator of
hemostasis by regulating fibrinolytic activity, PAI-1 plays a
role in many other (patho)physiological processes, including
wound healing, atherosclerosis, tumor angiogenesis, pul-
monary fibrosis, and rheumatoid arthritis.9–13 In addition,
PAI-1 acts as an acute phase protein during sepsis, with
enhanced plasma levels of PAI-1, accounting for the so-called
fibrinolytic shut down during severe sepsis.14,15
More recently, PAI-1 has been shown to be critically
involved in the regulation of cell migration. PAI-1 can inhibit
cell bound urokinase type plasminogen activator, resulting in
reduced pericellular proteolysis and a subsequent decrease in
cell migration. Furthermore, PAI-1 inhibits integrin- and
vitronectin-mediated cell migration independently of its
function as an inhibitor of plasminogen activation, by
competing for vitronectin binding to integrins.16 On the
contrary, the de-adhesive action of PAI-1 by inactivation of
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the cell-integrin-extra cellular matrix interaction, may result
in an increase of cell mobility as well.17 In addition, it has
been shown that PAI-1 in macrophages functions as a master
switch between cell adhesion and detachment by inducing
internalization of the aMb2 integrin/low density lipoprotein
receptor like protein (Mac-1/LRP) complex, thus promoting
macrophage migration.18
As a result, PAI-1 seems to exert both promoting and
inhibitory effects on cell migration. With respect to
neutrophil migration in reaction to infectious agents,
different roles for PAI-1 have been described. PAI-1 gene-
deficient (PAI-1/) mice have an unaltered immune
response to Streptococcus pneumoniae-induced pneumonia,
with similar pulmonary leukocyte recruitment in PAI-1/
and wild-type (WT) mice.19 Recently however, our labora-
tory showed that PAI-1/ mice have an impaired host
response during Klebsiella pneumoniae-induced pneumonia
and sepsis, associated with decreased pulmonary neutrophil
influx.20 Although upregulation of systemic PAI-1 levels
during E. coli-induced sepsis has been reported exten-
sively,21–24 the role of PAI-1 in host defense against E. coli
infections remains unclear.
To investigate the in vivo role of PAI-1 during UTI, we
induced acute pyelonephritis in PAI-1-deficient mice by
intravesical inoculation with uropathogenic E. coli.
RESULTS
PAI-1 expression is upregulated during acute pyelonephritis
To investigate local PAI-1 production on infection, renal
PAI-1 levels were measured by enzyme-linked immunosor-
bent assay (ELISA) after induction of acute pyelonephritis in
WT mice. Renal PAI-1 levels showed a twofold increase at
24 h after infection (Figure 1a). At 48 h, PAI-1 protein levels
approached baseline levels again (Figure 1a). To reveal the
cellular source of PAI-1, we performed in situ hybridization
on infected and sham kidneys. In sham kidneys, no positive
signal was detected (Figure 1b). The infected kidneys showed
clear positive signal for PAI-1 mRNA in endothelial cells of
arterioles (Figure 1c), veins (Figure 1d), and mononuclear
cells within the inflammatory infiltrates (Figure 1e).
Fibrinolytic parameters
As PAI-1 is one of the main inhibitors of fibrinolysis and
infections generally induce a procoagulant state, we analyzed
the amount of fibrin deposition by immunostainings and
levels of D-dimer in kidney homogenates by ELISA. No fibrin
deposits could be detected in WT and PAI-1/ kidneys at
both time points after inoculation with E. coli (not shown).
Furthermore, D-dimer levels were undetectable in kidney
homogenates of WT and PAI-1/ mice after infection (not
shown).
Higher bacterial load in PAI-1/ mice
Renal bacterial outgrowth was determined at 24 and 48 h
after infection. At both time points, PAI-1/ mice showed
a significantly higher number of E. coli colony-forming units
(CFU) in kidney homogenates than WT mice (Figure 2),
indicating that PAI-1/ mice had a seriously impaired
ability to clear E. coli-caused pyelonephritis.
In addition, PAI-1/ mice experienced more severe
systemic disease than WT mice. Blood cultures remained
negative in WT mice at both time points. In contrast, at 24 h
after infection, three out of nine PAI-1/ mice had positive
blood cultures. At 48 h, two out of seven PAI-1/ mice had
died (vs zero in WT mice) and one of the five remaining
PAI-1/ mice was bacteremic.
Lower neutrophil influx in bladders and kidneys from
PAI-1/ mice
As neutrophil recruitment plays a pivotal role in host defense
against bacterial infections, histological sections of bladder
and renal tissue were examined to investigate the extent of
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Figure 1 | Renal PAI-1 is upregulated during E. coli-induced
acute pyelonephritis. (a) PAI-1 protein levels in kidney
homogenates were measured by ELISA at 24 and 48 h after
inoculation. Data are mean±s.e.m., *Po0.05 vs sham mice. In situ
hybridization for murine PAI-1 mRNA was performed on paraffin
slides of sham (b) and infected kidneys (c–e). Arrows indicate the
urothelial cell layer of the renal pelvis. Twenty-four hours after
infection, positive signal in black. Original magnifications:  40.
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inflammation. WT kidneys showed an extensive pyelone-
phritis, whereas PAI-1/ kidneys showed virtually no
inflammation (Figure 3a). In both genotypes, neutrophils
were located in the lamina propria and urothelial cell layer,
with apparently fewer neutrophils in PAI-1/ kidneys
(Figure 3a). To quantify neutrophil influx, myeloperoxidase
(MPO) measurements on kidney homogenates were per-
formed by ELISA. In accordance with the histological
findings, neutrophil influx was significantly lower in
PAI-1/ mice than WT mice at 24 h (Figure 3b). At 48 h,
PAI-1/ kidneys tended to show lower MPO levels than
WT kidneys, although this trend did not reach statistical
significance (P¼ 0.06).
In accordance with these findings, at 24 h bladders of
PAI-1/ mice showed lower numbers of infiltrating
neutrophils than WT bladders (24 h: 76.3±13 (WT) vs
38.9±11 (PAI-1/) mean number of neutrophils/HPF
(Po0.05); 48 h: 23.1±14 (WT) vs 18.8±11 (PAI-1/)
mean number of neutrophils/HPF (P¼NS)).
To monitor the systemic inflammatory response and to
rule out a priori lower numbers of circulating neutrophils in
PAI-1/ mice, leukocyte numbers in the circulation
were counted. As shown in Figure 3c, sham WT and sham
PAI-1/ mice had similar white blood cell counts. On
infection, the number of peripheral leukocytes was upregu-
lated to the same extent in both genotypes (Figure 3c).
As intercellular adhesion molecule-1 (ICAM-1) and E-
selectin belong to the most important adhesion molecules
that enable neutrophil influx during pyelonephritis, and
expressions of ICAM-1 and E-selectin can be modified by the
fibrinolytic system,25 we analyzed immunostainings for
ICAM-1 and E-selectin. Quantitative assessment of ICAM-1
and E-selectin stainings showed similar expression in WT and
PAI-1/ mice (not shown).
Higher cytokine levels in PAI-1/ mice
As proinflammatory cytokines and chemokines play a crucial
role in the generation of an inflammatory response during
acute pyelonephritis,6,26 levels of IL-1b, IL-6, keratinocyte-
derived chemokine (KC), macrophage inflammatory protein-
2 (MIP-2), and tumor-necrosis factor-a (TNF-a) were
measured in kidneys at mRNA and protein level.
Both WT and PAI-1/ kidneys showed upregulation of
IL-1b, IL-6, MIP-2, and TNF-a mRNA at 24 h. As shown in
Table 1, PAI-1/ kidneys contained higher amounts of
MIP-2 and TNF-a mRNA than WT kidneys.
Protein levels of these cytokines were determined by
ELISA. Measurements are shown in Table 2. At 24 h, PAI-1/
kidneys contained higher levels of IL-1b than WT kidneys. At
48 h, renal levels of IL-1b and IL-6 protein were significantly
higher in PAI-1/ mice than in WT mice (Table 2). At both
time points, PAI-1/ kidneys contained higher levels of
TNF-a protein than WT kidneys.
The same cytokines were measured in plasma. Plasma levels
of IL-1b, IL-6, MIP-2, and TNF-a were too low to be detected
by ELISA (not shown). However, as shown in Figure 4, plasma
KC levels were significantly higher in PAI-1/ mice in
comparison with WT mice at both time points.
DISCUSSION
This study shows that endogenous PAI-1 is involved in host
defense during E. coli-induced acute pyelonephritis. PAI-1/
mice had a seriously impaired bacterial clearance when
compared to WT mice, at least, in part, caused by lower
influx of neutrophils into the infected renal tissue.
Elevated plasma levels of PAI-1 have been reported in
various clinical conditions, including pancreatitis, liver
disease, and various malignancies.27,28 In addition, PAI-1
has proven to act as an acute phase protein, with marked
elevation of plasma PAI-1 levels on surgery, myocardial
infarction, and during sepsis.14,15
Within the kidney, PAI-1 is normally produced in barely
measurable amounts.24 In this study, WT mice showed
increased renal PAI-1 mRNA and protein levels on inocula-
tion with E. coli, indicating a physiological role for PAI-1 in
host defense against acute pyelonephritis. Several kidney
diseases are associated with an upregulation of local PAI-1
production.29 Most of these concern conditions that are
associated with matrix accumulation, fibrin deposits, or
fibrosis, including diabetic nephropathy,30,31 membranous
nephropathy,32 thrombotic microangiopathy,33,34 and
chronic allograft nephropathy.35,36 Studies with genetically
engineered mice have demonstrated that PAI-1 exerts
profibrotic effects, as a result of its function as a proteolysis
inhibitor. Indeed, in experimental diabetic nephropathy and
obstructive nephropathy, PAI-1/ mice display signifi-
cantly reduced fibrosis in comparison with WT mice.37,38
PAI-1/ mice display a mild hyperfibrinolytic state and
have a quicker whole-blood clot lysis than WT mice.39 Fibrin
deposition has been implicated in the pathogenesis of
inflammatory glomerular diseases.40 In crescentic anti-
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Figure 2 | Higher bacterial outgrowth in PAI-1/ mice. At
T¼ 24 h and T¼ 48 h after inoculation, PAI-1/ kidneys (K)
contain higher E. coli CFU than WT kidneys (J). Horizontal lines
represent medians, *Po0.05; **Po0.01.
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glomerular basement membrane glomerulonephritis, tissue-
type plasminogen activator proved to be protective against
glomerular fibrin deposition and inflammation.41 In the
same disease model, PAI-1/ mice developed fewer
crescents, less glomerular fibrin deposition, and fewer
infiltrating leukocytes than WT mice.42 In accordance, mice
that overexpress PAI-1 show increased glomerular crescent
formation, more glomerular fibrin deposition, and more
glomerular inflammation than WT mice.42 Although fibrin
deposits have been described in severe acute pyelonephritis at
electron microscopic level,43 fibrin is not a regular feature of
this condition and probably not of pathogenetic significance.
In our model, no appreciable fibrin deposits were encoun-
tered and D-dimer levels were too low to be determined
effectively. This is in line with our previous study concerning
the role of tissue-type plasminogen activator in acute
pyelonephritis, where no fibrin deposits could be detected
using a highly specific western blotting technique (JJ Roelofs,
submitted for publication). Altogether, it seems unlikely that
differences in fibrin accumulation accounts for the more
severe UTI in PAI-1/ mice compared to WT mice.
The recruitment of neutrophils is a crucial part of host
defense against acute pyelonephritis.44 Our study shows that
PAI-1/ mice have a decreased ability to clear infection
with E. coli, at least partly due to diminished neutrophil
influx. Indeed, despite higher cytokine levels in PAI-1/
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Figure 3 | PAI-1/ mice show lower neutrophil influx during acute pyelonephritis. (a) Photomicrographs of WT and PAI-1/ renal
tissue, 24 h after infection. The upper panels show an overview of the pelvis region. The lower panels show a detail of the urothelial cell
layer of the renal pelvis. H&E staining, original magnifications:  4 (upper) and  40 (lower). (b) Myeloperoxidase (MPO) levels were
measured in kidney homogenates by ELISA. Data are mean±s.e.m., *Po0.05. (c) Peripheral blood leukocytes (WBC) were counted using a
hemocytometer. Data are mean±s.e.m., P¼NS.
Table 1 | Gene expression of pro-inflammatory cytokines by
QPCR
24 h
Gene expression/TBP WT PAI-1/
IL-1b 0.79±0.58 2.4±1.3a
IL-6 1.50±1.10 1.68±0.16
KC 0.10±0.07 0.09±0.07
MIP-2 1.0±1.0 5.9±5.2*
TNF-a 1.97±0.10 14.95±1.14*
KC, keratinocyte-derived chemokine; IL, interleukin; MIP-2, macrophage inflamma-
tory protein-2; PAI-1, plasminogen activator inhibitor type-1; TBP, TATA-binding
protein; TNF-a, tumor-necrosis factor-a; WT, wild type.
Data are expressed as amount of mRNA relative to housekeeping gene TBP;
mean±s.e.m., *Po0.05.
aP=0.05.
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kidneys compared to WT kidneys, less inflammation was
observed. The higher amount of CFU at 24 and 48 h after
inoculation were accompanied by higher levels of TNF-a, IL-
1b, and (at 48 h) IL-6 in the PAI-1/ kidneys. This is in line
with one of our previous studies, that showed that renal
cytokine levels are directly proportional to the amount of
CFU in this model.7 Indeed, After inoculation with
uropathogenic E. coli, bladder and tubular epithelial cells
have been shown to produce IL-1b, IL-6, IL-8, and TNF-a.4–6
Recent studies have shown that tubular epithelial cells
produce CXCL2 cytokines on inoculation with uropatho-
genic E. coli in a Toll-like receptor-4 (TLR-4)-mediated
fashion.45 In an elegant study involving a model of ascending
UTI in mice, Chassin et al.46 described that E. coli-infected
TLR-4-deficient mice fail to clear renal bacteria and exhibit
dramatically lower production of proinflammatory media-
tors in comparison to WT mice. In the same study it was
shown that uropathogenic E. coli stimulate primary cultures
of collecting duct intercalated cells both in a TLR4-mediated,
MyD88-dependent pathway and in a TLR4-independent
pathway, leading to bipolarized secretion of MIP-2 by renal
epithelial cells.46
Only one study describes an interaction between the
fibrinolytic system and TLR activity.47 This study describes
that plasmin potentiates TLR2 and TLR4 signaling in a
macrophage cell line in vitro. Plasmin enhances endogenous
production of TNF-a and activation of an nuclear factor-kB
reporter plasmid, in a proteolysis-dependent fashion. As we
measured higher TNF-a levels in our PAI-1/ mice, this
mechanism might be at play in our study as well. We
measured TLR-4 expression at 24 h. at the mRNA level by
quantitative PCR (QPCR). There were no significant
differences in TLR-4 expression levels between WT and
PAI-1/ mice (data not shown).
Our current observation that PAI-1 can exert proinflam-
matory protective effects is in accordance with a recent study
by Kwak et al.,48 that demonstrated that PAI-1 potentiates
lipopolysaccharide-induced neutrophil activation in vitro
through a c-Jun N-terminal kinase-mediated pathway.
Furthermore, these results are largely in accordance with a
previous report, which demonstrated that PAI-1 plays a
protective role during K. pneumoniae-induced pneumonia.20
In this study, PAI-1/ mice had higher bacterial outgrowth
than WT mice, associated with a reduction in pulmonary
neutrophil influx.20 Conversely, transgenic overexpression of
PAI-1 in the lung by means of a replication-defective
adenoviral vector resulted in reduction of bacterial out-
growth. Furthermore, PAI-1 overexpression in healthy (that
is, noninfected) lungs provoked neutrophil influx.20
A growing number of studies confirm a regulatory role for
PAI-1 in mobilization of various cell types. Apart from
regulating cell movement through plasmin-dependent extra
cellular matrix degradation,49,50 PAI-1 orchestrates cell
migration through modulation of urokinase plasminogon
activator receptor (uPAR) and integrin-mediated cell adhe-
sion.17,51 In general, PAI-1 exerts ‘de-adhesive’ actions,
resulting in either increased or decreased cell migration.16,17
As cell migration is the result of a dynamical balance between
adhesion, cytoskeleton modulation, and detachment, the net
effect of PAI-1 on cell movement depends strongly on the
cellular milieu and the applied experimental set up.
Another mechanism via which PAI-1 can influence
inflammatory cell migration, is the modification of chemo-
tactic gradients. Endothelial heparan sulfate (HS)-syndecan-1
ectodomains have the ability to bind and stabilize chemo-
kines, such as IL-8, thereby promoting neutrophil extravasa-
tion. IL-8–HS-syndecan-1 complexes are constitutively shed
by plasmin, which provides a negative regulation of IL-8-
mediated neutrophil migration. Marshall et al.52 have
demonstrated that PAI-1 negatively regulates the constitutive
shedding of endothelial IL-8–HS-syndecan-1 complexes.
Inhibition of PAI-1 activity through incubation with
neutralizing antibody MAI-12 induced the shedding of IL-
8–HS-syndecan-1 from endothelial cells in a concentration
dependent manner, resulting in diminished IL-8-mediated
transendothelial neutrophil migration.52 In addition, elevated
levels of soluble IL-8 have been shown to downregulate
functional IL-8 receptor on neutrophils53 and impede
neutrophil recruitment to inflammatory foci in vivo.54
Furthermore, transgenic mice that permanently overexpress
IL-8 exhibit a marked intravascular neutrophilia and
Table 2 | Proinflammatory cytokines and chemokines in
kidney homogenates
24 h 48 h
pg/mg Protein WT PAI-1/ WT PAI-1/
IL-1b 28.4±5.4 45.1±4.3* 25.6±5.5 51.8±11.2*
IL-6 6.7±1.2 7.3±1.4 5.2±0.8 14.1±4.2*
KC 234.3±29.4 249.7±37.1 217.8±22.1 213.3±14.8
MIP-2 41.0±4.7 40.8±7.8 47.0±9.7 45.5±5.3
TNF-a 8.8±3.4 16.5±2.9* 9.4±2.2 21.1±4.2*
IL, interleukin; KC, keratinocyte-derived chemokine; MIP-2, macrophage inflamma-
tory protein-2; PAI-1, plasminogen activator inhibitor type-1; TNF-a, tumor-necrosis
factor-a; WT, wild type.
Data are expressed as pg/mg protein; mean±s.e.m., *Po0.05.
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Figure 4 | Higher plasma KC levels in PAI-1/ mice. Plasma
KC levels were determined at 24 and 48 h after inoculation by
ELISA. Data are mean±s.e.m., *Po0.05.
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decreased neutrophil extravasation in response to inflamma-
tory stimulants.55 In a study on the role of PAI-1 in Gram-
negative pneumonia, it was demonstrated that PAI-1/
mice have elevated plasma levels of KC and impaired
pulmonary neutrophil influx.20 In this study, PAI-1/
mice displayed significantly elevated plasma levels of the
murine IL-8 homologue KC during pyelonephritis, whereas
KC levels in renal tissue were similar in WT and PAI-1/
mice. Most probably, PAI-1 deficiency caused increased
shedding of KC via the above-mentioned mechanism,
resulting in neutrophil ‘entrapment’ in the vascular compart-
ment. In particular with respect to acute pyelonephritis, IL-8
has been shown to be a key chemokine to promote
neutrophil recruitment to the urinary compartment.56 It
has been shown that IL-8 receptor is of critical importance
for neutrophils to cross the urothelial basement membrane
and launch an adequate host response on infection with
uropathogenic E. coli.57,58 Furthermore, very recently IL-8
gene polymorphisms have been implicated in susceptibility to
acute pyelonephritis in a pediatric population.59
Taken together, this study provides new evidence for a
protective role for PAI-1 during E. coli-induced acute
pyelonephritis through the promotion of neutrophil
migration.
MATERIALS AND METHODS
Mice and experimental protocol
Female PAI-1/ mice on a C57BL/6J background60 were
purchased from The Jackson Laboratory (Bar Harbor, ME, USA)
and bred in the institutional animal facilities. Mice were backcrossed
more than 12 times. Age- and weight-matched C57Bl/6J mice
(Charles River, Maastricht, The Netherlands) served as a WT
control.
UTI was induced as described previously.7,61 E. coli 1677, isolated
from a uroseptic patient, was donated by Dr. W.J. Hopkins
(University of Wisconsin Medical School, Madison). This strain
has virulence factors that include type 1 and P fimbriae, hemolysin,
and aerobactin.62 This specific serotype has proven uropathogenicity
in mice.61,62 Bacteria were cultured for 16 h at 37 1C in trypticase soy
broth. After dilution 1:100 in fresh trypticase soy broth, the
suspension was grown for 3 h to midlogarithmic phase. E. coli were
washed three times in sterile phosphate-buffered saline. After
resuspension in phosphate-buffered saline, the final concentration
was determined by plating 10-fold serial dilutions of the suspension
on blood agar plates. Acute pyelonephritis was induced under
general anesthesia (0.07 ml/10 g mouse of fentanyl–fluanisone–mi-
dazolam mixture, containing 1.25 mg/ml midazolam (Roche,
Mijdrecht, The Netherlands), 0.08 mg/ml fentanyl citrate and
2.5 mg/ml fluanisone (Janssen Pharmaceutica, Beerse, Belgium)) in
8- to 10-week old female mice. Bacterial suspension (100 ml) was
administered transurethrally through a 0.55 mm catheter (Abbott,
Zwolle, The Netherlands). Sham control mice (n¼ 5 per group)
underwent the same procedure with administration of 100 ml of
sterile phosphate-buffered saline instead of bacterial suspension.
Mice killed at 24 h after inoculation (n¼ 9 per group) received
2.7 108 CFU per mouse. In a separate experiment, mice killed at
48 h after inoculation (n¼ 7 per group) received 1.0 109 CFU per
mouse. The choice of these time points was based on the literature
and on our own broad experience with this model.7,61–63 White
blood cell counts in peripheral blood were determined using a
hemocytometer (Beckman Coulter, Fullerton, CA, USA). The
Committee on Use and Care of Animals of the Academic Medical
Center at the University of Amsterdam approved all experiments.
Animal experimentation guidelines were followed in all experi-
ments.
Determination of bacterial outgrowth
Bacterial load was determined in renal tissue and blood as described
earlier.7,61 One half of the left kidney from each mouse was
homogenized in 4 volumes of sterile saline with a tissue
homogenizer which was cleaned with 70% ethanol after each
homogenization. Serial 10-fold dilutions were made in sterile saline,
and 50 ml volumes of kidney homogenate and blood were plated
onto blood agar plates, which were incubated at 37 1C for 16 h, after
which E. coli CFU were counted.
Histological examination
The bladder and the remaining part of the left kidney were fixed in
10% formalin and embedded in paraffin. Sections were stained with
hematoxylin and eosin in a standard fashion. Neutrophils in the
bladder were counted in four randomly chosen fields ( 400
magnification).
Immunostaining for fibrin, ICAM-1, and E-selectin were
performed as described previously,64 using anti-mouse fibrin(ogen)
(Ixell; Accurate Chemical & Scientific, Westbury, NY, USA), anti-
mouse ICAM-1 (R&D Systems, Minneapolis, MN, USA), and anti-
mouse E-selectin (R&D Systems) as primary antibodies. The
amount of ICAM-1 and E-selectin staining was measured as
described previously64 in eight randomly chosen fields ( 200
magnification) using digital image analysis (Image pro-plus;
Mediacybernetics, Dortmund, Germany).
Murine PAI-1 mRNA in situ hybridization was performed using
radiolabeled [35S]-UTP (Amersham, Arlington Heights, IL, USA)
mouse (NM_008871, bp 680–823) PAI-1-specific riboprobes, as
described previously.20,65 In short, 7-mm-thick paraffin sections of
renal tissue were pretreated with proteinase K (20 mg/ml) for 5 min,
refixed in 4% paraformaldehyde, and treated for 10 min with 0.25%
acetic anhydride in 0.1 mol/l triethanolamine. Hybridizations were
performed overnight at 50 1C (0.5 mCi probe) per section under a
cover slip in a moist chamber. After hybridization, slides were
washed in 50% formamide, 2 saline-sodium citrate, and
10 mmol/l dithiothreitol. After RNase A digestion, washing and
dehydration, autoradiography emulsion was applied (Ilford G5
emulsion 1:1 diluted with 2% glycerol). Slides were developed in
Kodak D19 after an exposure of 3–6 weeks, fixed in Kodak UNIFIX,
and counterstained with hematoxylin.
Real-time quantitative PCR analysis
Real-time QPCR analysis was performed using RNA obtained from
kidneys from WT and PAI-1/ mice, at T¼ 24 h. Total RNA was
isolated using TRIzol LS Reagent (Invitrogen Life Technologies,
Breda, The Netherlands), following the manufacturer’s instructions.
The concentration and purity of RNA were determined spectro-
photometrically at 260/280 nm. Five micrograms of total RNA was
reverse-transcribed into cDNA using oligo dT primers (Roche).
Primer sets used were IL-1b: forward CTGCAGCTGGAGAGTGTG
GAT, reverse GCTTGTGCTCTGCTTGTGAG; IL-6: forward CAAA
GCCAGAGTCCTTCAGAG, reverse TGGTCCTTAGCCACTCCTTC;
KC: forward ATAATGGGCTTTTACATTCTTTAACC, reverse
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AGTCCTTTGAACGTCTCTGTCC; MIP-2: forward CCCTGGTTCA
GAAAATCATCC, reverse CTTCCGTTGAGGGACAGC; TNF-a:
forward TCGTAGCAAACCACCAAGTG, reverse CCTTGTCCCTTG
AAGAGAACC; TLR-4: forward GGACTCTGATCATGGCACTG,
reverse CTGATCCATGCATTGGTAGGT. TATA-binding protein
was used as housekeeping gene: forward GGAGAATCATGGACCA
GAACA, reverse GATGGGAATTCCAGGAGTCA. QPCR was per-
formed with a LightCycler LC480 (Roche). For the PCR, a master
mixture was prepared on ice, containing per sample: 1 ml of cDNA,
1 ml of FastStart Reaction Mix SYBR Green I (Roche Applied
Science, Indianapolis, IN, USA), 0.5 ml of 10 mM primers, and 1.6 ml
of 25 mM MgCl2. After the reaction mixture was loaded into a glass
capillary tube, the cycling conditions were carried out as follows:
initial denaturation at 95 1C for 6 min, followed by 45 cycles of
denaturation at 95 1C for 15 s, annealing at 55–60 1C for 5–10 s, and
extension at 72 1C for 8–12 s. The temperature transition rate was set
at 20 1C/s. Fluorescent product was measured by a single acquisition
mode at 72 1C after each cycle. Quantification of data was performed
using the standard Light Cycler analysis software. The amount of
amplified cytokine products was divided by the amount of TATA-
binding protein for each sample.
PAI-1, cytokine, MPO, and D-dimer measurements
The right kidney of each mouse was homogenized in phosphate-
buffered saline containing 1% Triton X-100, 1 mM EDTA (Merck,
Schiphol, The Netherlands), and 1% protease inhibitor cocktail
(P8340, Sigma, Zwijndrecht, The Netherlands). Levels of PAI-1, IL-
1b, IL-6, KC, MIP-2, TNF-a, mouse MPO, and D-dimer in kidney
homogenates and plasma were measured by specific ELISA
according to the instructions of the manufacturer (PAI-1: Molecular
Innovations Inc., Southfield, MI, USA; IL-1b, IL-6, KC, MIP-2, and
TNF-a: R&D systems; MPO: HyCult Biotechnologies, Uden, The
Netherlands; D-dimer: Diagnostica Stago, Asnie`res sur Seine,
France). Total protein content of the samples was determined
according to the method of Bradford,66 using a commercially
available protein assay kit (Bio-Rad, Hercules, CA, USA).
Statistical analysis
All data are presented as mean±standard error of the mean, unless
stated otherwise. Data were analyzed by Mann–Whitney U-test or
unpaired Student’s t-test when appropriate. Po0.05 was considered
to represent a statistically significant difference.
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